Tolerability of diclofenac sodium 1% gel with concomitant medications known to interact with diclofenac
John H Peniston,1 Morris S Gold,2 Matthew S Wieman,3 Lawrence K Alwine4 1Feasterville Family Health Care Center, Feasterville, PA, 2Novartis Consumer Health, Inc, Parsippany, NJ, 3Endo Pharmaceuticals Inc, Malvern, PA, 4Downingtown Family Medicine, Downingtown, PA, USA Background: Topical diclofenac...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2013-04-01
|
Series: | Therapeutics and Clinical Risk Management |
Online Access: | http://www.dovepress.com/tolerability-of-diclofenac-sodium-1-gel-with-concomitant-medications-k-a12775 |
id |
doaj-8d2b2377f1d0426ca6cacce4ae4c0e72 |
---|---|
record_format |
Article |
spelling |
doaj-8d2b2377f1d0426ca6cacce4ae4c0e722020-11-24T21:59:52ZengDove Medical PressTherapeutics and Clinical Risk Management1176-63361178-203X2013-04-012013default153159Tolerability of diclofenac sodium 1% gel with concomitant medications known to interact with diclofenacPeniston JHGold MSWieman MSAlwine LKJohn H Peniston,1 Morris S Gold,2 Matthew S Wieman,3 Lawrence K Alwine4 1Feasterville Family Health Care Center, Feasterville, PA, 2Novartis Consumer Health, Inc, Parsippany, NJ, 3Endo Pharmaceuticals Inc, Malvern, PA, 4Downingtown Family Medicine, Downingtown, PA, USA Background: Topical diclofenac sodium 1% gel (DSG) has demonstrated efficacy and tolerability in patients with osteoarthritis (OA) of the knees or hands, including elderly patients and those with an increased risk of gastrointestinal, cardiovascular, and renal adverse events (AEs). Medications known to interact with diclofenac were disallowed in a clinical trial of DSG for knee OA; however, patients were not to be discontinued for intake of disallowed treatment, unless there was a safety issue. This post hoc analysis examined the frequency and type of AEs in patients who received DSG concomitantly with drugs known to have potential interactions with diclofenac. Materials and methods: This was a post hoc analysis of a randomized controlled trial of DSG for knee OA pain. Patients (n = 254) aged ≥ 35 years with OA in one or both knees, but with clinical OA symptoms in only one knee, administered DSG topically to the target knee four times daily (total dose, 16 g/d) for 12 weeks. Drugs with the potential for major or moderate drug–drug interactions (DDIs) were identified via Drugs.com. AE rates were compared in patients with versus those without ≥1 potential DDI. Results: At least one AE was experienced by 62.6% (107/171) of patients with ≥1 DDI and by 55.4% (46/83) of patients with no DDIs. Gastrointestinal AEs (upper and lower) were reported in 5.3% (9/171) and 7.2% (6/83), cardiovascular AEs in 4.7% (8/171) and 1.2% (1/83), renal AEs in 1.2% (2/171) and 0%, and hepatic AEs in 0% and 1.2% (1/83) of patients with ≥1 DDI compared with patients with no DDIs, respectively. Conclusion: Concurrent use of DSG with medications that had potential for major to moderate DDIs had little impact on the frequency of AEs in this population. Further research is needed to consider how factors such as dose, duration, and timing of concomitant drug administration may affect the likelihood of clinically evident AEs resulting from a potential DDI. Keywords: drug interactions, nonsteroidal anti-inflammatory drugs, topical administration, knee osteoarthritishttp://www.dovepress.com/tolerability-of-diclofenac-sodium-1-gel-with-concomitant-medications-k-a12775 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Peniston JH Gold MS Wieman MS Alwine LK |
spellingShingle |
Peniston JH Gold MS Wieman MS Alwine LK Tolerability of diclofenac sodium 1% gel with concomitant medications known to interact with diclofenac Therapeutics and Clinical Risk Management |
author_facet |
Peniston JH Gold MS Wieman MS Alwine LK |
author_sort |
Peniston JH |
title |
Tolerability of diclofenac sodium 1% gel with concomitant medications known to interact with diclofenac |
title_short |
Tolerability of diclofenac sodium 1% gel with concomitant medications known to interact with diclofenac |
title_full |
Tolerability of diclofenac sodium 1% gel with concomitant medications known to interact with diclofenac |
title_fullStr |
Tolerability of diclofenac sodium 1% gel with concomitant medications known to interact with diclofenac |
title_full_unstemmed |
Tolerability of diclofenac sodium 1% gel with concomitant medications known to interact with diclofenac |
title_sort |
tolerability of diclofenac sodium 1% gel with concomitant medications known to interact with diclofenac |
publisher |
Dove Medical Press |
series |
Therapeutics and Clinical Risk Management |
issn |
1176-6336 1178-203X |
publishDate |
2013-04-01 |
description |
John H Peniston,1 Morris S Gold,2 Matthew S Wieman,3 Lawrence K Alwine4 1Feasterville Family Health Care Center, Feasterville, PA, 2Novartis Consumer Health, Inc, Parsippany, NJ, 3Endo Pharmaceuticals Inc, Malvern, PA, 4Downingtown Family Medicine, Downingtown, PA, USA Background: Topical diclofenac sodium 1% gel (DSG) has demonstrated efficacy and tolerability in patients with osteoarthritis (OA) of the knees or hands, including elderly patients and those with an increased risk of gastrointestinal, cardiovascular, and renal adverse events (AEs). Medications known to interact with diclofenac were disallowed in a clinical trial of DSG for knee OA; however, patients were not to be discontinued for intake of disallowed treatment, unless there was a safety issue. This post hoc analysis examined the frequency and type of AEs in patients who received DSG concomitantly with drugs known to have potential interactions with diclofenac. Materials and methods: This was a post hoc analysis of a randomized controlled trial of DSG for knee OA pain. Patients (n = 254) aged ≥ 35 years with OA in one or both knees, but with clinical OA symptoms in only one knee, administered DSG topically to the target knee four times daily (total dose, 16 g/d) for 12 weeks. Drugs with the potential for major or moderate drug–drug interactions (DDIs) were identified via Drugs.com. AE rates were compared in patients with versus those without ≥1 potential DDI. Results: At least one AE was experienced by 62.6% (107/171) of patients with ≥1 DDI and by 55.4% (46/83) of patients with no DDIs. Gastrointestinal AEs (upper and lower) were reported in 5.3% (9/171) and 7.2% (6/83), cardiovascular AEs in 4.7% (8/171) and 1.2% (1/83), renal AEs in 1.2% (2/171) and 0%, and hepatic AEs in 0% and 1.2% (1/83) of patients with ≥1 DDI compared with patients with no DDIs, respectively. Conclusion: Concurrent use of DSG with medications that had potential for major to moderate DDIs had little impact on the frequency of AEs in this population. Further research is needed to consider how factors such as dose, duration, and timing of concomitant drug administration may affect the likelihood of clinically evident AEs resulting from a potential DDI. Keywords: drug interactions, nonsteroidal anti-inflammatory drugs, topical administration, knee osteoarthritis |
url |
http://www.dovepress.com/tolerability-of-diclofenac-sodium-1-gel-with-concomitant-medications-k-a12775 |
work_keys_str_mv |
AT penistonjh tolerabilityofdiclofenacsodium1gelwithconcomitantmedicationsknowntointeractwithdiclofenac AT goldms tolerabilityofdiclofenacsodium1gelwithconcomitantmedicationsknowntointeractwithdiclofenac AT wiemanms tolerabilityofdiclofenacsodium1gelwithconcomitantmedicationsknowntointeractwithdiclofenac AT alwinelk tolerabilityofdiclofenacsodium1gelwithconcomitantmedicationsknowntointeractwithdiclofenac |
_version_ |
1716614320222109696 |